News

MyChesCo on MSN4d
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial
New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...
AstraZeneca’s potential blockbuster pill halves high cholesterol
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...
Fierce Biotech11d
AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...
Healio3d
Daily oral PCSK9 inhibitor cut LDL cholesterol by 50% over 12 weeks
In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...
NBC Washington11d
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...
AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial
AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
News Nation on MSN2d
AstraZeneca’s pill cuts cholesterol, offers convenient treatment
AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...